#### Edgar Filing: Tracon Pharmaceuticals, Inc. - Form SC 13G/A

Tracon Pharmaceuticals, Inc. Form SC 13G/A January 22, 2018 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)<sup>1</sup> TRACON Pharmaceuticals, Inc. (Name of Issuer) Common Stock, \$.001 par value (Title of Class of Securities) 89237H100 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d)

<sup>&</sup>lt;sup>1</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

# CUSIP No. 89237H100

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON		
1.	Johnson & Johnson EIN: 22-1024240		
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP SEC USE ONLY	(a) (b)	[]
3.	SEC USE ONL I		
4.	CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey		
NUMBER OF SHARES	<ul><li>5. SOLE VOTING POWER</li><li>6. SHARED VOTING POWER</li><li>7. SOLE DISPOSITIVE POWER</li></ul>	-0- 840,022 -0-	
BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	8.SHARED DISPOSITIVE POWER	840,022	
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON CHECK BOX IF THE	840,022	
10.	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	[]	
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	4.8%	
12.	TYPE OF REPORTING PERSON	CO	

<sup>\*</sup> Based on 17,511,928 shares of Common Stock outstanding as of November 3, 2017, as reported in the Issuer's Report on Form 10Q for the period ended September 30, 2017 filed with the Securities and Exchange Commission on November 7, 2017.

# CUSIP No. 89237H100

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON		
1.	Johnson & Johnson Innovation-JJDC, Inc. EIN: 22-2007137		
<ol> <li>3.</li> </ol>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP SEC USE ONLY	(a) [ ] (b) [ ]	
4.	CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey		
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH	7. SOLE DISPOSITIVE POWER	-0- 840,022 -0-	
REPORTING PERSON WITH	8. SHARED DISPOSITIVE POWER	840,022	
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON CHECK BOX IF THE	840,022	
10.	AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES PERCENT OF CLASS	[]	
11.	REPRESENTED BY AMOUNT IN ROW (9)	4.8%	
12.	TYPE OF REPORTING PERSON	CO	

<sup>\*</sup> Based on 17,511,928 shares of Common Stock outstanding as of November 3, 2017, as reported in the Issuer's Report on Form 10Q for the period ended September 30, 2017 filed with the Securities and Exchange Commission on November 7, 2017.

CUSIP No. 89237H100

3

## AMENDMENT NO. 1 TO SCHEDULE 13G (FINAL AMENDMENT)

Reference is hereby made the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on October 31, 2016 (the "Schedule 13G"). Terms defined in the Schedule 13G are used herein as so defined.

The following items of the Schedule 13G are amended and restated to read in their entirety as follows:

#### OWNERSHIP:

#### ITEM (a) through (c)

4

The information requested hereunder is incorporated by reference to the cover pages to this Amendment No. 1 to Schedule 13G.

#### OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

If this statement is being filed to report the fact that the Reporting Persons have ceased to be beneficial owners ITEM of more than five percent of the Common Stock, check the following: [X].
5

# Edgar Filing: Tracon Pharmaceuticals, Inc. - Form SC 13G/A

## CUSIP No. 89237H100

## **SIGNATURE**

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: January 22, 2018

#### **JOHNSON & JOHNSON**

By: /s/ Thomas J. Spellman III Name: Thomas J. Spellman III

Title: Secretary

JOHNSON & JOHNSON INNOVATION-JJDC, INC.

By: /s/ Kevin Norman Name: Kevin Norman Title: Assistant Secretary

5